Patents by Inventor Miro VIITALA

Miro VIITALA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TLR9 AGONISTS FOR USE IN DOWNREGULATING CLEVER-I EXPRESSION ON ALTERNATIVELY ACTIVATED MACROPHAGES
    Publication number: 20210371865
    Abstract: The invention relates to use of TLR9 antagonist in a method for treating cancer and/or chronic infection by downregulating Clever-1 expression on alternatively activated immunosuppressive macrophages.
    Type: Application
    Filed: November 1, 2019
    Publication date: December 2, 2021
    Applicant: FARON PHARMACEUTICALS OY
    Inventors: Maija-Leena HOLLMÉN, Miro VIITALA
  • TREATMENT OF CANCER WITH CLEVER-1 INHIBITION IN COMBINATION WITH PD-1/PD-L1 INHIBITOR
    Publication number: 20210261657
    Abstract: The invention relates to an agent capable of binding to CLEVER-1 in combination with PD-1 and/or PD-L inhibitor for use in a treatment of cancer.
    Type: Application
    Filed: June 20, 2019
    Publication date: August 26, 2021
    Applicant: FARON PHARMACEUTICALS OY
    Inventors: Maija-Leena HOLLMÉN, Miro VIITALA
  • ANTI-CLEVER-1 AGENTS FOR CONTROLLING LYSOSOMAL VATPASE PROTON PUMPS TO INCREASE LYSOSOMAL PH-VALUE AND THE CROSS-PRESENTATION OF DIGESTED MATTER
    Publication number: 20210087264
    Abstract: A method of determining the efficacy of anti-Clever-1 therapy by measuring lysosomal pH, and a method of increasing lysosomal pH for improving an activation of the immune system in a patient, in which method an agent that inhibiting Clever-1 on the lysosomal proton pump (vATPase) is administered to a patient.
    Type: Application
    Filed: September 24, 2020
    Publication date: March 25, 2021
    Applicant: Faron Pharmaceuticals Oy
    Inventors: Maija-Leena HOLLMÉN, Miro VIITALA, Jenna RANNIKKO
  • Method of monitoring the efficacy of the anti-clever-1 therapy in cancer
    Patent number: 10884000
    Abstract: An agent capable of binding to CLEVER-1 in an individual can be used in activating macrophages to switch their phenotype from M2 macrophages into M1 macrophages. The invention relates to methods for utilizing the macrophages ability to switch their phenotype. In one aspect, the invention relates to a method for estimating of the efficacy of anti-CLEVER-1 therapy by monitoring a modulation of M2 macrophages into M1 macrophages, when an agent capable of binding to CLEVER-1 is administered in a patient, wherein an increased TNF-alpha secretion or HLA-DR expression is indicative of modulation of M2 macrophages into M1 macrophages.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: January 5, 2021
    Assignee: Faron Pharmaceuticals Oy
    Inventors: Maija-Leena Hollmén, Miro Viitala, Markku Jalkanen, Mikael Maksimow
  • DIAGNOSIS OF IMMUNE_ACTIVATION USING CLEVER-1, TNF-ALPHA AND HLA-DR BINDING AGENTS
    Publication number: 20190064180
    Abstract: An agent capable of binding to CLEVER-1 in an individual can be used in activating macrophages to switch their phenotype from M2 macrophages into M1 macrophages. The invention relates to methods for utilizing the macrophages ability to switch their phenotype. In one aspect, the invention relates to a method for estimating of the efficacy of anti-CLEVER-1 therapy by monitoring a modulation of M2 macrophages into M1 macrophages, when an agent capable of binding to CLEVER-1 is administered in a patient, wherein an increased TNF-alpha secretion or HLA-DR expression is indicative of modulation of M2 macrophages into M1 macrophages.
    Type: Application
    Filed: April 18, 2017
    Publication date: February 28, 2019
    Applicant: FARON PHARMACEUTICALS OY
    Inventors: Maija-Leena HOLLMÉN, Miro VIITALA, Markku JALKANEN, Mikael MAKSIMOW